Recent Events

ReviveMed is proud to announce that we are pursuing an evaluation study with Bristol Myers Squibb (NYSE: BMY). This study will leverage ReviveMed’s artificial intelligence (AI) platform to better understand mechanisms of response and resistance to immunotherapies in patients with cancer. [mkd_blockquote text="“We are very excited about...